CytomX Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $228.35M.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $93.37M, a 1828.00% increase year-over-year.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $4.84M.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $107.71M.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2025 was $93.37M, a 1251.47% increase from fiscal 2024.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2024 was $6.91M.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $107.71M, a 854.22% increase from fiscal 2020.
- CytomX Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $11.29M, a 604.62% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $228.35M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $93.37M 10-K · filed 2026-03-16 | |
| 2025-06-30 | $93.37M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $6.91M 10-K · filed 2025-03-06 | |
| 2024-06-30 | $4.84M 10-Q · filed 2025-11-06 | |
| 2021-12-31 | $107.71M 10-K/A · filed 2023-03-27 | |
| 2021-03-31 | $107.71M 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $11.29M 10-K/A · filed 2023-03-27 | |
| 2019-12-31 | $1.60M 10-K/A · filed 2023-03-27 | |
| 2019-06-30 | $1.60M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $134.60M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $134.60M 10-Q · filed 2019-11-07 | |
| 2016-12-31 | $159.00K 10-K · filed 2018-03-07 | |
| 2015-12-31 | $81.76M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |